Sanofi brings patent infringement case in New York against Merck Inc. in relation to insulin glargine biosimilar.
Sanofi announced have brought on 8 August 2017 an infringement action against Merck Sharp & Dohme Corp. ("Merck") in the district court of New Jersey (United States District Court for the District of New Jersey), in the United States. The Sanofi complaint about infringement of two patents.
The complaint was prompted by a notification, received from Merck late June, in which Merck is said to have applied to the FDA for approval new drug (New Drug Application - NDA (505 (b) (2)) for insulin glargine in a bottle. Merck also stated that its application for approval included a certification "paragraph IV", challenging all Sanofi patents listed in the Orange Book of the FDA for Lantus� and Lantus� SoloStar� from Sanofi products.
Comment: The FDA has issued a tentative approval for Lusduna (insulin glargine biosimilar) in July 2017 and the biosimilar was EU approved in January 2017.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins